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Summary
Background Epidemiological studies strongly suggest that psoriasis predisposes to
type 2 diabetes. Several theories have been proposed to explain how these disease
entities might be pathophysiologically connected.
Objectives Our primary objective was to elucidate whether clinical data support the
notion of common pathophysiological denominators in patients with psoriasis
and type 2 diabetes, and thus to delineate the association between the two condi-
tions that has arisen on the basis of epidemiological studies.
Methods We reviewed clinical studies investigating parameters of glucose metabo-
lism in patients with psoriasis. The PubMed and Embase databases were searched
for studies investigating glucose metabolism in adult patients with psoriasis as a
primary or secondary end point. Studies had to include a relevant control group.
Results Twenty-six clinical studies reporting on insulin resistance, glucose tolerance
or insulin secretion were eligible for review. The results were widely conflicting,
with less than half of the studies showing results suggestive of defective glucose
metabolism in patients with psoriasis. In general, the studies suffered from a lack
of information regarding possible confounders and patient characteristics. Further-
more, the research methods varied, and in all but one study they might not have
been appropriate to detect early and subtle defects in glucose metabolism.
Conclusions The available literature does not unequivocally support common patho-
physiological denominators in psoriasis and type 2 diabetes. Well-designed clini-
cal studies are needed to expose potential diabetogenic defects in the glucose
metabolism in patients with psoriasis.
What’s already known about this topic?
• Large epidemiological studies have concluded that psoriasis predisposes to type 2
diabetes, and there seems to be a dose–response relationship with severe psoriasis
associated with a higher risk of developing type 2 diabetes.
• Several theories of how these diseases might be connected have been proposed.
• These are based mostly on the chronic inflammatory state shared by the two condi-
tions.
What does this study add?
• We reviewed clinical studies investigating glucose metabolism in patients with pso-
riasis and found that the clinical evidence supporting epidemiology-based hypothe-
ses pathophysiologically connecting psoriasis and type 2 diabetes is inconclusive.
• The methods used were suboptimal and the results ambiguous.
• Well-designed studies are warranted to determine whether psoriasis itself consti-
tutes a prediabetic condition or whether the development of type 2 diabetes in
patients with psoriasis comprises an epiphenomenon.
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Psoriasis is a multifactorial immune-mediated chronic inflam-
matory skin disease associated with an extensive range of
comorbidities including cardiovascular disease, metabolic syn-
drome, depression and type 2 diabetes (T2D).1 Like psoriasis,
T2D is a complex disease with a multifactorial aetiology.
According to the World Health Organization, the worldwide
prevalence of diabetes has doubled since 1980 and shows no
signs of regressing.2
T2D is characterized by insulin resistance in skeletal muscle
and adipose tissue (collectively named peripheral insulin resis-
tance) and in the liver (central or hepatic insulin resistance), as
well as impaired insulin secretion from pancreatic beta cells.3
In the progression from normal glucose tolerance through pre-
diabetes to overt T2D there is initially a phase of normal fasting
and postprandial glucose levels maintained by compensatorily
increased insulin secretion from pancreatic beta cells.4 Predia-
betes and T2D develop when the beta cells are not capable of
secreting enough insulin to keep up with the insulin resistance,
resulting in relative insulin deficiency and increasing plasma
glucose levels (Fig. 1). Insulin resistance, dysfunction of the
insulin-secreting beta cells and impaired glucose tolerance are
thus early signs of disturbances in glucose metabolism appear-
ing prior to the development of overt T2D.4
Epidemiological studies strongly support an association
between psoriasis and T2D,5–10 and several lines of evidence
point to a dose–response effect, with more severe psoriasis
associated with a higher risk of T2D.5,6,9,10 Thus, epidemio-
logical data firmly suggest that psoriasis predisposes to T2D,
but the pathophysiological link between psoriasis and T2D is,
as yet, poorly understood.
With the epidemiological evidence uniformly pointing to
an association between psoriasis and the risk of developing
T2D, we set out to provide a critical review of clinical studies
examining glucose metabolism in patients with psoriasis. The
aim was to investigate whether patients with psoriasis display
the well-known early signs of disturbances in glucose metabo-
lism seen in the progression to T2D.
Methods
All studies on adult patients with psoriasis investigating any
form of glucose metabolism as primary or secondary end
points were taken into consideration. The search for relevant
studies was conducted in the PubMed and Embase databases.
Search terms were psoriasis, glucose, insulin, insulin resis-
tance, insulin sensitivity, glucose metabolism, homeostasis
Hepatic insulin resistance Peripheral insulin resistance
Insulin secretion
Environment, genetics, obesity, lifestyle
Plasma glucose increase
Before prediabetes
- Insulin resistance
- Increased compensatory insulin secretion
- Normal plasma glucose levels
- Normal glucose tolerance
Type 2 diabetes
- Increased insulin resistance
- Further progression of beta cell failure
- Further elevation of plasma glucose (to 
levels diagnostic for type 2 diabetes)
- Over time macro- and microvascular
complications
Skeletal muscle: 
decreased glucose 
uptake
Adipose tissue: increased 
lipolysis. Fatty acids used as 
energy instead of glucose. 
Glycerol a substrate for 
gluconeogenesis
Liver: increased hepatic 
glucose production
Pancreatic beta cells: initially respond 
by increasing insulin production. Over 
time progressive beta cell failure and 
decreased insulin secretion
Prediabetes
- Increased insulin resistance
- Progressive beta cell failure
- Rising plasma glucose levels
- Impaired glucose tolerance
(Time)
Fig 1. The development of type 2 diabetes. This figure was created using Servier Medical Art, licensed under the Creative Commons Attribution
30 Unported License: http://creativecommons.org/licenses/by/30.
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model assessment, oral glucose tolerance test, clinical study,
beta cell and hyperinsulinaemic euglycaemic clamp. All search
terms were used in various relevant combinations and in the
Medical Subject Headings search builder tool in PubMed. All
studies were screened for relevance based on the abstract avail-
able. Studies written in a language other than English and
studies without a control group of persons without psoriasis
were not taken into consideration. Studies that reported only
blood-sample values of insulin, glucose and glycated haemo-
globin A1c without using methods to study specific aspects of
glucose metabolism were also excluded. References in papers
already included were examined for relevance. We identified a
total of 26 eligible studies, presented in Table S1 (see Sup-
porting Information). The study selection process is illustrated
in Figure 2.
Overview of the clinical studies
Insulin resistance
The hyperinsulinaemic euglycaemic clamp is considered the
gold standard of measuring whole-body insulin resistance. A
standardized amount of insulin is infused continuously
(enough to shut down hepatic glucose production) and an
adjustable intravenous glucose infusion is used to maintain
euglycaemia. The amount of glucose infused during a prede-
fined steady-state period is denoted the M-value and used as a
marker of insulin sensitivity (or, reciprocally, insulin resis-
tance).11 Patients with T2D are typically insulin resistant and
thus have a low M-value.12
Only one descriptive hyperinsulinaemic euglycaemic clamp
study has specifically investigated insulin resistance in
patients with psoriasis.13 This study found that patients with
moderate-to-severe psoriasis [Psoriasis Area and Severity
Index (PASI) > 8]14 were significantly more insulin resistant
than controls matched for age, sex and body mass index
(BMI): median (interquartile range) M-value 45 (16–140)
vs. 74 (21–108) mg kg1 min1, P = 0046. The two
groups did not differ regarding habitual physical activity,
fasting plasma glucose, glycated haemoglobin A1c and predis-
position to T2D.
The hyperinsulinaemic euglycaemic clamp requires signifi-
cant resources with its advanced set-up, but if done correctly
it provides a detailed comparison of insulin resistance between
groups. A much simpler but less precise way of investigating
insulin resistance is using the homeostasis model assessment
(HOMA). The HOMA index is based on a mathematical mod-
elling of fasting plasma glucose and plasma insulin. In the
fasting state the glucose level is predominantly controlled by
the liver (hepatic glucose production). Hepatic glucose pro-
duction is sensitive to insulin. Thus, the HOMA index will
mainly evaluate hepatic insulin sensitivity or resistance. It is
applied in research to estimate both insulin resistance
(HOMA-IR) and beta cell function (HOMA-B). Usually,
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Fig 2. PRISMA flow diagram of the study selection process. From Moher et al. PLOS Med 2009; 6:e1000097.67
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patients with T2D have higher HOMA-IR and lower HOMA-B
values than controls.15
In total, 17 studies have investigated insulin resistance in
patients with psoriasis compared with controls using HOMA-
IR (Table S1; see Supporting Information).16–32 Eight studies
found a higher degree of insulin resistance in patients with
psoriasis than in controls.19,20,22,26,28,29,31,32 Two studies
showed inconclusive results23,27 (marked with a ‘?’ in
Table S1) and six studies found no difference between
groups.16–18,21,24,25 One study even reported a significantly
decreased HOMA-IR in the patient group.30 Interestingly, only
three26,29,32 of eight studies matching for BMI16,21,
24–26,29,30,32 showed significantly increased insulin resistance.
As alluded to above, epidemiological studies have revealed
a positive correlation between psoriasis disease severity and
risk of developing T2D.5,6,9,10 In five of the HOMA-IR stud-
ies mentioned above, the mean PASI of the included patients
was high (> 8), reflecting severe disease.18,20,21,27,29 These
studies all found some sign of impaired glucose metabolism,
albeit of differing character. Two studies found a significantly
higher HOMA-IR in the patients with psoriasis than in con-
trols.20,29 Two studies showed higher fasting plasma insulin
levels or HOMA-B value18,21 but no difference in HOMA-IR.
The last study found that patients with psoriasis more fre-
quently had HOMA-IR > 25, were characterized by higher
fasting plasma insulin levels and had a higher prevalence of
diabetes.27 Unfortunately, a majority of the studies had no
requirement regarding the severity of psoriasis in the inclu-
sion criteria.
As evident from the above results and summarized in
Table S1, clinical studies investigating insulin resistance in
psoriasis display conflicting results. Notably, the only gold
standard hyperinsulinaemic euglycaemic clamp study per-
formed showed a greater degree of insulin resistance in
patients with psoriasis than in matched controls.
Glucose tolerance
The oral glucose tolerance test (OGTT) is a dynamic test and
closely resembles physiological conditions, with gastric empty-
ing and absorption and release of glucose-regulating hor-
mones all contributing to glucose tolerance. After the patient
has fasted overnight, a set amount of glucose is dissolved in
water and ingested orally. Blood samples are obtained at speci-
fied time points. The fasting or 2-h value of plasma glucose
can be used in the diagnosis of diabetes. High levels indicate
diabetes, while midrange values classify a person as having
impaired fasting glucose (IFG) or impaired glucose tolerance
(IGT), which are characteristics of prediabetes.33
As illustrated in Table S1 (see Supporting Information), in
total, nine studies used the OGTT to investigate glucose metabo-
lism in patients with psoriasis compared with controls.32,34–41
The results of the OGTTs were presented as the prevalence of
IFG, IGT or overt T2D. Only two of the studies39,40 found sig-
nificantly higher rates of IGT or T2D in patients with psoriasis.
Even though this is only two studies, their results are worth
highlighting as these studies were large and they accounted
for several risk factors for T2D. Pereira et al.40 studied 77
patients with plaque psoriasis. Patients and controls were
matched with regard to BMI, family history of diabetes and
smoking. Patients with psoriasis had an odds ratio of 263 (95%
confidence interval 137–504, P = 0003) of having an abnor-
mal glucose metabolism (IFG, IGT or diabetes) compared with
controls. Ucak et al.39 examined patients with psoriasis with no
previous history of IGT and no family history of diabetes and
compared them with age-, sex- and BMI-matched controls.
They found that 186% of the patients with psoriasis vs. 25% of
the controls had IGT. The HOMA-IR was also increased in
the psoriasis group. The remaining studies found no signifi-
cant difference regarding IGT or diabetes between the
groups.32,34–38,41
Similar to the studies investigating insulin resistance, the
collated evidence from the OGTT studies reviewed above, and
summarized in Table S1, is inconclusive. Only two of the nine
studies showed significantly impaired glucose tolerance in
patients with psoriasis.
Pancreatic beta cell function
The function of the pancreatic beta cell is a key part of glu-
cose metabolism.42 It has scarcely been investigated in patients
with psoriasis, even though direct measurements of pancreatic
beta cell function can be made relatively simply, for example
by an intravenous glucose tolerance test.43 Another simple
method is the utilization of the HOMA-B index. Two21,39 of
three studies16,21,39 using HOMA-B showed increased beta cell
function in patients with psoriasis. Other studies18,38 found
significantly elevated insulin levels in patients with psoriasis,
but no insulin resistance or impaired glucose tolerance.
Despite the scarcity of studies and their limited sizes, current
evidence suggests that patients with psoriasis are characterized
by hypersecretion of insulin – most likely as a consequence of
insulin resistance (see Fig. 1).
Epidemiological studies on the association
between psoriasis and type 2 diabetes
As mentioned briefly in the introduction, the evidence from
the epidemiological literature has suggested that psoriasis is
associated with T2D and, intriguingly, that there exists a
dose–response effect with more severe psoriasis associated
with a higher risk of T2D.5,6,9,10 Three comprehensive meta-
analyses all found a significant association between psoriasis
and the prevalence and/or incidence of diabetes.6,7,9 How-
ever, they all have some notable reservations to consider.
There was a sizeable degree of heterogeneity in the studies
included. The heterogeneity mainly stemmed from the
method of data collection, namely questionnaires, clinical
assessment and a billing database. All three studies also com-
mented on the risk of confounding given that most studies
lacked information regarding known risk factors of T2D
including obesity, physical activity levels and medical history
© 2018 British Association of Dermatologists British Journal of Dermatology (2019) 180, pp264–271
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of diabetes. Lastly, the possibility of bias could not be
excluded, especially regarding recall and selection bias in the
case–control studies. The epidemiological evidence of an asso-
ciation between the two diseases appears convincing, but it
cannot provide an explanation of the mechanism(s) underly-
ing this association.
The pathophysiological link between psoriasis
and type 2 diabetes
The exact pathophysiological mechanism(s) linking psoriasis
and T2D is unknown. Several theories have been proposed,
which include shared genetic variations and risk factors.
There is also an emphasis on the proinflammatory cytokines
present as a result of the systemic inflammation that occurs
in both psoriasis and T2D.44 Systemic inflammation in severe
psoriasis leads to the development of comorbidities such as
diabetes and cardiac diseases, which then impact the selec-
tion of appropriate systemic therapy.45 Patients with psoriasis
have a deregulated immune system (Fig. 3). Inflammatory
myeloid dendritic cells release interleukin (IL)-23 and IL-12,
which activate IL-17-producing T cells, T helper (Th)1 cells
and Th22 cells.46 These cells stimulate the production of
proinflammatory cytokines including IL-1, IL-6 and tumour
necrosis factor (TNF)-a, which, besides playing a pivotal part
in the pathogenesis of psoriasis47 have been shown to inter-
fere with insulin signalling and induce apoptosis in beta
cells.48,49
Intriguingly, it has been suggested that insulin plays a key
role in the differentiation of keratinocytes.50,51 Insulin resis-
tance in human keratinocytes caused by the proinflammatory
cytokine IL-1b could be responsible for the lack of differentia-
tion and uncontrolled proliferation seen in psoriatic plaques.52
IL-1b has long been known to be involved in the pathogenesis
of psoriasis47 and causes insulin resistance in muscle, adipose
tissue and liver cells.53–55 It may therefore constitute a patho-
physiological link between diabetes and psoriasis. These possi-
ble mechanisms indicate that the low-grade inflammation
present in patients with psoriasis might lead to insulin resis-
tance, an important precursor of T2D (Fig. 3).
Shared gene variants exist in both diseases. Several genetic
psoriasis susceptibility loci (PSORS) have been identified.
PSORS2, PSORS3 and PSORS4 are associated with susceptibility
loci of metabolic diseases including T2D.56 Through genome-
wide association studies a host of single-nucleotide polymor-
phisms (SNPs) linked to psoriasis have been uncovered.46
While the function and thus pathophysiological consequence
of gene mutations in these susceptibility loci and SNPs are not
fully elucidated it has been shown that some of these con-
tribute to the state of chronic inflammation seen in both
Deregulated immune system
Myeloid dendric cells
Proinflammatory cytokines
IL-1β, IL-6, TNF-α etc.
Hepac insulin resistance
Beta cell apoptosis Peripheral insulin resistance
Psoriasis plaques
Insulin resistance in 
keranocytes
Type 2 diabetes
IL-12, IL-17, IL-23
IL-1β
Fig 3. Theoretical role of inflammation in the shared pathogenesis of psoriasis and type 2 diabetes. Overactive myeloid dendritic cells release
interleukin (IL)-23 and IL-12, which activate IL-17-producing T cells, T helper (Th)1 cells and Th17 cells. These cells stimulate the production of
proinflammatory cytokines including IL-1, IL-6 and tumour necrosis factor (TNF)-a, which interfere with insulin signalling and lead to plaque
production. IL-1b might induce plaque psoriasis by inhibiting insulin-dependent keratin differentiation and control of proliferation. This figure
was created using Servier Medical Art, licensed under the Creative Commons Attribution 30 Unported License: http://creativecommons.org/lice
nses/by/30.
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psoriasis and diabetes.46 For instance, a gene mutation in the
caspase recruitment domain-containing protein 14 gene
(CARD14), located in PSORS2, ultimately leads to recruitment
of neutrophils, dendritic cells and T cells, resulting in an
increased production of inflammatory cytokines.46 Another of
these shared genetic defects is a mutation in the CDK5 regula-
tory subunit associated protein 1-like 1 gene (CDKAL1), which
is thought to inhibit the pancreatic beta cells’ response to
plasma glucose.57 Normally, pancreatic beta cells respond
directly and proportionally to a rise in plasma glucose by pro-
ducing and secreting more insulin.
Lastly, the connection between psoriasis and T2D may sim-
ply rely on the fact that many independent risk factors for
T2D including smoking, inactivity and obesity1 are more
prevalent in patients with psoriasis than in the general popula-
tion. Also, stigmatizing psoriatic skin lesions can be thought
to catalyse an unhealthy, secluded lifestyle increasing the risk
of developing T2D. This would make T2D an epiphenomenon
to psoriasis.
Comments on the available evidence from
clinical studies
A number of clinical studies, including one gold standard
hyperinsulinaemic euglycaemic clamp study, point to defective
glucose metabolism in patients with psoriasis. This is in line
with the evidence derived from epidemiological studies. Stud-
ies investigating patients with severe psoriasis were more con-
sistent and generally showed signs of deranged glucose
metabolism, which is in agreement with the dose–response
relationship observed in epidemiological studies. Nevertheless,
the overall evidence from clinical studies in the field is far
from convincing.
The OGTT was used as a diagnostic test in some of the
included studies determining normal glucose tolerance, IGT
and T2D.32,34–41 It is well known that the OGTT is character-
ized by a high intraindividual variation in the 2-h plasma glu-
cose concentration, resulting in a low reproducibility of the
IGT category in particular. In a study of an elderly white pop-
ulation without a history of diabetes (n = 555) the repro-
ducibility of the OGTT performed on two different days was
91% for normal glucose tolerance, 48% for IGT and 78% for
T2D.58 Considerations regarding power calculations and sam-
ple size are therefore crucial for the interpretation of OGTT
results. Only three of the studies included information on
power calculations13,19,32 and none of these were OGTT stud-
ies. Several studies highlighted a small sample size as a limita-
tion to their study,17,24,27,37,41 while the rest did not address
this issue. Therefore, many of the included studies might be
too small or underpowered to draw firm conclusions from.
Less than half of the studies showed significant changes in
the parameters of glucose metabolism they investigated. Fur-
thermore, only six of 12 BMI-matched studies suggested
impaired glucose metabolism in patients with psoriasis. The
roles of lifestyle factors such as smoking, alcohol and physical
inactivity were rarely taken into account. Furthermore, there
was a general lack of information regarding the patient group
characteristics, concomitant medication, disease severity and
predisposition to T2D. Compared with epidemiological stud-
ies, clinical studies should ideally be designed to control for
these confounders, but most of the studies identified in this
review failed to do so (Table S1; see Supporting Information).
Thus, the increased risk of T2D found in the epidemiologi-
cal studies might simply be explained by the fact that typical
risk factors for T2D are more prevalent in patients with psori-
asis. In that case, early lifestyle interventions would reduce the
risk of developing T2D to the level of the background
population.
There are some important points in favour of a clinically
significant association between the two diseases. The hyper-
insulinaemic euglycaemic clamp study13 showed increased
insulin resistance in patients with psoriasis. No difference
was found in the HOMA-IR index in the same study. This
may suggest that HOMA-IR, and maybe the OGTT method
as well, are not sensitive enough to discover subtle differ-
ences in glucose metabolism between groups. That would
explain the conflicting results of the clinical studies
reviewed here.
Interestingly, it has been demonstrated that patients with
psoriasis have a significantly decreased incretin effect com-
pared with age- and sex-matched controls.59 Impairment of
the incretin effect has been speculated to constitute an early
disturbance in glucose metabolism,60 and the same could be
true in patients with psoriasis.
There have also been some crossover effects in the concur-
rent treatment of the two diseases. Treatment with the anti-
TNF-a drugs etanercept and adalimumab, commonly used in
the treatment of psoriasis, has been shown to exert positive
effects on insulin sensitivity.61,62 This is in agreement with
the theory that inflammatory cytokines are involved in the
pathogenesis of both diseases.47,48 On the other hand, a
hyperinsulinaemic euglycaemic clamp study on the positive
effect of anti-inflammatory treatment on insulin resistance was
cancelled halfway through when no trend was observed.63
More treatment studies are needed to clarify whether early
anti-inflammatory treatment might prevent the development
of T2D in patients with psoriasis.
Similar to the studies investigating the effect of anti-inflam-
matory treatment on insulin resistance, the effects of antidia-
betic drugs on psoriasis have been studied on several
occasions. Intriguingly, there are a number of reports that
treatment with antidiabetic drugs can have positive effects on
psoriasis.64 If that were indeed the case then it would be sug-
gestive of a common pathogenesis. The reports cover different
antidiabetic treatments, for example glucagon-like peptide-1
receptor agonists (GLP-1RAs), dipeptidyl peptidase 4 inhibi-
tors, thiazolidinediones and biguanides. However, a relief of
psoriasis symptoms due to antidiabetic drugs has been seen
mainly in small studies so far.64 Two randomized placebo-
controlled studies with a GLP-1RA65 and thiazolidinediones66
failed to show a beneficial effect of antidiabetic drugs on
psoriasis.
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Finally, important information regarding glucose metabo-
lism in patients with psoriasis is still missing in order to
confirm whether psoriasis constitutes a state comparable
with prediabetes, and thus can accurately be classified as
an individual risk factor for T2D. Prediabetes describes a
state where plasma glucose is higher than normal but
below the cut-off value for diabetes. All of the mecha-
nisms involved in glucose metabolism may contribute to
this elevation of plasma glucose, including but not limited
to hepatic insulin resistance, peripheral insulin resistance
and beta cell dysfunction resulting in IFG, IGT or both
(Fig. 1). As shown in this review these parameters of glu-
cose metabolism have not been investigated extensively
enough, in particular regarding hepatic insulin resistance
and beta cell function. Uncovering specific pathological
changes in glucose metabolism in patients with psoriasis
could lead to better preventive strategies and novel treat-
ment targets, improving the general health and quality of
life of these patients.
Conclusions
The results of clinical studies investigating glucose metabolism
in patients with psoriasis are conflicting and it seems pre-
sumptuous to conclude firmly that patients with psoriasis
share glucometabolic impairments with people with predia-
betes. However, seen in conjunction with the epidemiological
literature and the proposed theories of a shared pathophysiol-
ogy, there is ample basis for further research in this area. New
studies using sound methods and elaborate research tech-
niques are needed for further characterization of the glucose
metabolism in patients with psoriasis.
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